Reduction of acquired resistance to anti cancer drug in cultured cells through photodynamic therapy
| Project/Area Number |
15K01296
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 生体制御・治療 / 光線力学療法 |
|---|
| Outline of Final Research Achievements |
In this study, we evaluated the potential of PDT to reduce acquired resistance to anticancer agents in cell types over-expressing P-glycoprotein (P-gp), a membrane-bound drug efflux transporter. Photofrin(PF) was used as the photosensitizing agent. Irradiation was performed in the range of 0.5-3.0 J/cm2, which did not lead to any significant cytotoxic effect. The contact between PF and target cells was facilitated by adding PF in (1) a serum-containing culture medium (Protocol 1), and (2) phos-phate-buffered saline (Protocol 2). HeLa cells were incubated in these two culture media. A comparative assessment was employed to evaluate the capacity of PDT to reduce acquired resistance to paclitaxel (TXL) in these cells. Although there was no significant reduction in TXL resistance by PDT in Protocol 1, a decrease in drug efflux activity was obtained in Protocol 2, indicating a reduction in TXL resistance.
|
Report
(4 results)
Research Products
(4 results)
